Abstract
Colorectal cancer (CRC) is a heterogeneous disease entity in terms of both molecular carcinogenesis and morphologic carcinogenesis multistep pathways. Considerable heterogeneity exists within CRC due to the varied genetic and epigenetic mechanisms involved in different carcinogenesis pathways. A better understanding of pathophysiology of tumors is necessary to develop modern and successful means of treatment in metastatic CRC. Over the last 5 years, there has been a surge in interest in the molecular classification of colorectal cancer, as its clinical importance both for predicting prognosis and in guiding personalized treatment had been acknowledged. Recently, the Colorectal Cancer Subtyping Consortium identified four consensus molecular subtypes, CMS 1-4 in CRC; however, attempts to stratify CRC using molecular features for prognostic and predictive purposes in clinical conditions had limited success. In this review, we focused on molecularly defined subtypes of CRC including specific mutations and discuss implications for current and future patient management in metastatic CRC to achieve the maximal therapeutic response for each patient, while reducing adverse side effects of therapy.
Keywords: Consensus molecular subtypes, colorectal cancer, chemotherapy, carcinogenesis, chromosomal instability, microsatellite instability.
Current Drug Targets
Title:Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer
Volume: 19 Issue: 15
Author(s): Marcin Włodarczyk*, Jakub Włodarczyk, Paweł Siwiński, Aleksandra Sobolewska-Włodarczyk and Jakub Fichna
Affiliation:
- Department of Biochemistry, Medical University of Lodz, Lodz,Poland
Keywords: Consensus molecular subtypes, colorectal cancer, chemotherapy, carcinogenesis, chromosomal instability, microsatellite instability.
Abstract: Colorectal cancer (CRC) is a heterogeneous disease entity in terms of both molecular carcinogenesis and morphologic carcinogenesis multistep pathways. Considerable heterogeneity exists within CRC due to the varied genetic and epigenetic mechanisms involved in different carcinogenesis pathways. A better understanding of pathophysiology of tumors is necessary to develop modern and successful means of treatment in metastatic CRC. Over the last 5 years, there has been a surge in interest in the molecular classification of colorectal cancer, as its clinical importance both for predicting prognosis and in guiding personalized treatment had been acknowledged. Recently, the Colorectal Cancer Subtyping Consortium identified four consensus molecular subtypes, CMS 1-4 in CRC; however, attempts to stratify CRC using molecular features for prognostic and predictive purposes in clinical conditions had limited success. In this review, we focused on molecularly defined subtypes of CRC including specific mutations and discuss implications for current and future patient management in metastatic CRC to achieve the maximal therapeutic response for each patient, while reducing adverse side effects of therapy.
Export Options
About this article
Cite this article as:
Włodarczyk Marcin *, Włodarczyk Jakub , Siwiński Paweł, Sobolewska-Włodarczyk Aleksandra and Fichna Jakub , Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer, Current Drug Targets 2018; 19(15) . https://dx.doi.org/10.2174/1389450119666180803122744
| DOI https://dx.doi.org/10.2174/1389450119666180803122744 |
Print ISSN 1389-4501 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Camptothecin: Therapeutic Potential and Biotechnology
Current Pharmaceutical Biotechnology Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn’s Disease and Ulcerative Colitis
Current Pharmaceutical Design Adhesion Molecules in Lung Cancer: Implications in the Pathogenesis and Management
Current Pharmaceutical Design Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Perspectives in Medicinal Chemistry: Metallomics and New Targets in Metal-Based Drug Discovery
Current Topics in Medicinal Chemistry Dietary Phytochemicals in Chemoprevention of Cancer
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry Antioxidant Treatment for Acute Pancreatitis
Recent Patents on Inflammation & Allergy Drug Discovery Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology Emerging Therapeutic Potential of Whey Proteins and Peptides
Current Pharmaceutical Design The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Beyond the Selective Inhibition of Histone Deacetylase 6
Mini-Reviews in Medicinal Chemistry CCK Receptors and Cancer
Current Topics in Medicinal Chemistry Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer’s Disease
Current Alzheimer Research In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Construction and Analysis of mRNA and lncRNA Regulatory Networks Reveal the Key Genes Associated with Prostate Cancer Related Fatigue During Localized Radiation Therapy
Current Bioinformatics The Role of COX-2 in Heart Pathology
Cardiovascular & Hematological Agents in Medicinal Chemistry Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials
Current Angiogenesis (Discontinued)

